# An Observational Study on Sarilumab-exposed Pregnancies

> **NCT03378219** · — · COMPLETED · sponsor: **Sanofi** · enrollment: 113 (actual)

## Conditions studied

- Rheumatoid Arthritis -Exposure During Pregnancy

## Interventions

- **DRUG:** Sarilumab SAR153191 (REGN88)

## Key facts

- **NCT ID:** NCT03378219
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2024-12-06
- **Final completion:** 2024-12-06
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03378219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03378219, "An Observational Study on Sarilumab-exposed Pregnancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03378219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*